Available online at http://www.journalcra.com

International Journal of Current Research
Vol. 9, Issue, 05, pp.51506-51511, May, 2017

INTERNATIONAL JOURNAL OF CURRENT RESEARCH

ISSN: 0975-833X

RESEARCH ARTICLE

HPLC-MS/MS METHOD DEVELOPMENT AND VALIDATION FOR DETERMING STABILITY OF ALECTINIB IN HUMAN PLASMA SAMPLES

***Srikanth, I. and Prameela Rani, A.**

Department of Pharmaceutical Sciences, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur-522510

ARTICLE INFO

Article History:
Received 27th February, 2017
Received in revised form
29th March, 2017
Accepted 07th April, 2017
Published online 31st May, 2017

Key words:
Alectinib,
Human Plasma,
HPLC-ESI-MS/MS
Bioanalysis.

ABSTRACT

The validated protein precipitation method was applied for estimation of AT in human plasma with ATD8 as an internal standard (ISTD) by using HPLC-ESI-MS/MS. The chromatographic separation was achieved with 0.1% formic acid in combination with methanol (25:75 v/v) using the C_{18} column Ascentis Express (50 mm × 4.6 mm, 2.7 µm). The total analysis time was 3 min and flow rate was set to 0.6 ml/min. The mass transitions of AT, ATD_8 obtained were m/z 482.6→396.0 and 490.6→396.0. The standard curve shows correlation coefficient (r^2) greater than 0.9983 with a range of 5.00-10000.00 pg/ml using the linear regression model.

Citation: Srikanth, I. and Prameela Rani, A. 2017. Hplc-ms/ms method development and validation for determing stability of alectinib in human plasma samples", *International Journal of Current Research*, 9, (05), 51506-51511.

INTRODUCTION

Alectinib (AT) *is* 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile with chemical formula $C_{30}H_{34}N_4O_2$ (Fig.1) and its molecular weight is 482.61656. Alectinib was used for the treatment of anaplastic lymphoma kinase (ALK) inhibitor (Hiroaki *et al*., 2016; Dobbelstein *et al*., 2014; Prideaux, 2012; Sugiura, 2010; Bennet *et al*., 2013). The literature survey reveals that, a variety of methods were reported on the pharmacokinetics of Alectinib in human plasma (Kim, 2008; Gode, 2013; Seeley, 2011) for quantification of Alectinib by using HPLC-MS/MS. From the literature review it was concluded that the reported methods used highly expensive extraction process (SPE), long run time and lack of deuterated internal standard by using HPLC-ESI-M/MS methods. There is no method reported for estimation of Alectinib using deuterated internal standard in biological samples. The main goal of the present study is to develop and validate the novel simple, sensitive, selective, rapid, rugged and reproducible analytical method for quantitative determination of AT in human plasma by HPLC-ESI-MS/MS with a small amount of sample volume.

Corresponding author: **Srikanth, I.**
Department of Pharmaceutical Sciences, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur-522510.

MATERIALS AND METHODS

Materials

Chemical Resources

Alectinib and AlectinibD8 (VARDA Biotech, Mumbai, India), methanol and acetonitrile (J.T Baker, USA), formic acid (Merck, Mumbai, India), Ultra pure water (Milli-Q system, Millipore, Bedford, MA, USA), human plasma (Doctors pathological labs, hyderabad, India). The chemicals and solvents were used in this study analytical and HPLC grade.

Instrument Resources

An API 4000 HPLC-ESI-MS/MS system (Applied Biosystems), 1200 Series HPLC system (Agilent Technologies, Waldbronn, Germany), data acquisition and processing were accomplished using Analyst® Software 1.4.1.

Methods

Chromatographic conditions

The chromatographic separation was achieved with 0.1% formic acid in combination with methanol (25:75 v/v), gave the best peak shape and low baseline noise was observed using the Ascentis Express C_{18} (50 mm × 4.6 mm, 2.7 µm).



Fig.1: Chemical structures of A) Alectinib B) AlectinibD8



Fig. 2. Mass fragmentation pattren of Alectinib (AT)

Table. 1 - Calibration curve details

Spiked plasma Concentration (pg/ml)	Concentration measured (pg/ml) (Mean±S.D)	%CV (n=5)	%Accuracy
5.00	4.99±0.01	1.4	99.9
10.00	10.24±0.02	3.6	101.7
50.00	49.89±0.15	2.7	101.3
100.00	100.24±0.22	2.5	100.1
500.00	501.6±0.27	3.8	100.1
1000.00	1004.22±0.21	2.6	101.7
2000.00	1999.18±1.02	3.1	99.4
4000.00	4001.35±1.10	3.4	101.7
6000.00	6003.76±1.11	1.7	102.6
8000.00	8001.12±1.96	3.8	101.5
10000.00	10000.07±1.23	2.5	100.5

The total analysis time was 3 min and flow rate was set to 0.6 ml/min. The temperature was set to 40°C for the column oven. The sample volume for the injection into mass spectrometry was adjusted to 10 µl for better ionization and chromatography.

Detection

The pure drug of AT and ATD_8 were prepared in methanol (10.00 ng/mL) and injected with a flow rate of 5 µL/min into positive ion mode mass spectrometer for optimization of mass parameters like source temperature, IS, heater gas, nebulizer gas, curtain gas, CAD gas (all gas channels were purged with ultra high pure nitrogen gas), EP, DP, CE, FP and CXP were optimized. Analysis was performed using MRM positive ion mode with mass transitions of m/z (amu) 482.6→396.0 and 490.6→396.0 for AT and ATD_8.The mass fragmentation pattern of parent and product ions mass spectras were depicted in Figure 2.

Calibration standards (5.00, 10.00, 50.00, 100.00, 500.00, 1000.00, 2000.00, 4000.00, 6000.00, 8000.00 and 10000.00 pg/ml), quality control samples of lower limit QC, low QC, mid QC, high QC (5.00, 15.00, 3000.00, 7000.00 pg/ml) were used by spiking the appropriate amount of standard solution in the drug free plasma and stored at -30 ℃ till analysis.

Sample extraction

The protein precipitation method was applied to extract AT and ATD8. To each labelled polypropylene tube 50 µl of ATD8 (500.00 ng/ml) was mixed with the 100 µl plasma sample, then 0.25 ml of acetonitrile were added, vortexed for 5 min and centrifuged at 4000 rpm for 10 min at 20°C. The organic phase was transferred to auto sampler vials containing 100 µl of 0.1% formic acid and injected into the HPLC-ESI-MS/MS for analysis.

Method validation

The developed method was validated over a linear concentration range of 5.0–10000.0 pg/ml.



Fig. 3. Mass fragmentation pattren of Alectinib D8 (ATD8)

Standard calibration and quality control samples preparation

Stock solutions of AT (1000.00 µg/ml) and ATD8 (1000.00 µg/ml) were prepared in methanol. The internal standard (ATD8) spiking solution (500.00 ng/ml) was prepared in 75% methanol from ATD8 stock solution. Stock solutions of AT, ATD8 and intermediate spiking solutions were stored in refrigerated conditions (2-8℃) until analysis.

The validation parameters include selectivity and specificity, LOQ, Linearity, precision and accuracy, matrix effect, recovery, stability (freeze–thaw, auto sampler, bench top, long term) was evaluated under validation section.

Selectivity and Specificity

Ten lots of blank plasma samples were analyzed out of which six lots free from interference were selected for assessing

the selectivity and specificity. The endogenous/potential interfering peak areas for blank samples must be less than 20% of the LLOQ peak area of AT retention time and less than 5% for ATD8 retention time.

Limit of Quantification (LOQ)

Six LLOQ standards were prepared in screened plasma lot along with IS (500.00 ng/ml) and signal to noise ratio (S/N) was calculated using analyst software.

Linearity

Calibration standards were prepared to obtain linearity range of 5.00, 10.00, 50.00, 100.00, 500.00, 1000.00, 2000.00, 4000.00, 6000.00, 8000.00 and 10000.00pg/ml and assayed in five replicates on five different days.

Precision & Accuracy

One set of calibration standards and one set contains four different concentrations of quality control standards of Lower limit QC (5.00 pg/ml), Low QC (15.00 pg/ml), Mid QC (3000.00 pg/ml) and High QC (7000.00 pg/ml) concentrations were prepared in screened plasma and analyzed each quality control (QC) standards in six replicates on the same day (Intra day) and five different days (Inter day).

Matrix Effect

Six extracted blank plasma samples in three replicates were spiked with the un-extracted concentration of mid QC (3000.00 pg/ml) and compared with un-extracted standards of the same concentration.

Recovery

The recovery of samples was performed by protein precipitation method.The extraction recovery was determined in sextuplicate by comparing the extracted QC standards with un-extracted QC standards at three different concentrations of low (15.00 pg/ml), medium (3000.00 pg/ml), high (7000.00 pg/ml).

Stability studies

Bench top Stability (Room Temperature Stability, 24 h)

Six replicates of spiked low and high concentrations (BT stability samples) were set aside at ambient temperature up to 24 h. Samples were processed and compared with newly prepared low and high concentrations (comparison samples).

Freeze and thaw stability (after 3rd cycle at -30°C)

Six replicates of low and high concentrations (FT stability samples) were frozen at -30°C and subjected to three freeze-thaw cycles of 24, 36 and 48 h (-30°C to room temperature) and compared with newly prepared low and high concentrations (comparison samples).

Autosampler stability (2-8°C, 65 h)

Six replicates of low and high concentrations (AS stability samples) were stored in auto-sampler up to 65 h at 2-8°C. Stability samples were compared with newly prepared low and high concentrations (comparison samples).

Long-term Stability (-30°C, 45 Days)

After completion of the stability period stored at -30 °C (45 days) six replicates of low and high concentrations (LT stability samples) were compared with newly prepared low and high concentrations (comparison samples).

RESULTS AND DISCUSSION

Method development

On the way to develop a simple and easy applicable method for determination of AT in human plasma, HPLC-MS/MS was selected as the method of choice. During method development process chromatographic (mobile phase composition, column, flow rate, injection volume, sample volume), mass spectrometric, sample extraction and internal standard parameters were optimized in logical and sequential manner to achieve the best results. Separation of the AT was performed with different branded RP-HPLC C_{18} columns. Initial separation was performed with isocratic elution of 10mM ammonium formate and acetonitrile was selected as a mobile phase in varying combinations were tried, but a low response was observed. A mobile phase consisting of 0.1% acetic acid: acetonitrile (20:80 v/v) and 0.1%acetic acid: methanol (20:80 v/v) gave the best response, but poor peak shape was observed. After a series of trials a mobile phase consisting of 0.1% formic acid in combination with methanol and acetonitrile in varying combinations were tried.

Using a mobile phase containing 0.1% formic acid in combination with methanol (25:75 v/v), gave the best signal along with a marked improvement in the peak shape and low baseline noise was observed using the Ascentis Express C_{18} (50 mm × 4.6 mm, 2.7 µm) analytical column with a flow rate of 0.6 ml/min and reduced runtime to 3 min. The column oven temperature was kept at a constant temperature of about 40 °C and temperature of auto sampler was maintained at 4°C. Injection volume of 10 µl sample was adjusted for better ionization and chromatography. For selection of internal standard, Afatinib Dimaleate, Imatinib Mesylate and Lenvatinib Mesylate were tried with optimized mobile phase and column conditions. Finally AlectinibD8 (VLD_9) was selected as internal standard in terms of better chromatography and extractability.

The retention times of analyte (AT) and internal standard (ATD8) were eluted at 1.42 ± 0.2 min and 1.44 ± 0.2 min respectively with 3 min total runtime. Different procedures like PPT (Protein precipitation), SPE (solid phase extraction) and LLE (liquid-liquid extraction) methods were optimized. Out of all, it was observed that the PPT was suitable due to simple extraction, high recovery and the less ion suppression effect on drug and internal standard. Electro spray ionization (ESI) provided a maximum response over atmospheric pressure chemical ionization (APCI) mode, and was chosen for this method. The instrument was optimized to obtain sensitivity and signal stability during infusion of the analyte in the continuous flow of mobile phase to electrospray ion source operated at a flow rate of 20 µl/min. Alectinib gave more response in positive ion mode as compare to the negative ion mode.



Fig.4. Representative chromatograms of Alectinib in plasma a) Blank plasma chromatogram for interference free AT and ATD8 b) Chromatogram of LLOQ sample (AT with ATD8)

Table 2. Precision and accuracy (Analysis with spiked samples at three different concentrations)

Spiked Plasma Concentration (pg/ml)	Within-run (Intra-day)			Between-run (Inter-Day)		
	Concentration measured (n=6;pg/ml;mean±S.D)	%CV	%Accuracy	Concentration measured (n=6;pg/ml;mean±S.D)	%CV	%Accuracy
15.00	14.8±0.07	5.10	94.78	14.9±0.08	3.2	91.66
3000.00	3002.34±1.23	2.36	96.00	2999.78±2.56	1.6	99.34
7000.00	6999.47±2.45	3.35	94.17	7004.33±3.61	2.4	97.55

Table. 3 - Stability studies of Alectinib in plasma

Spiked Plasma concentration (pg/ml)	Room temperature Stability		Processed sample Stability		Long term stability		Freeze and thaw stability	
	24h		65h		45 days		Cycle (48h)	
	Concentration measured (n=6;pg/ml; mean±S.D)	%CV (n=6)	Concentration measured (n=6;pg/ml; mean±S.D)	%CV (n=6)	Concentration measured (n=6;pg/ml; mean±S.D)	%CV (n=6)	Concentration measured (n=6;pg/ml; mean±S.D)	%CV (n=6)
15.00	14.9±0.12	7.8	15.5±2.16	5.3	15.2±1.54	8.8	14.8±0.12	5.8
7000.00	7005.3±0.14	8.9	7001.3±1.23	9.4	6999.563±0.12	9.4	7001.4±2.55	2.7

To get high intense productions source dependent parameters were optimized like nebulizer gas flow 30 psi, CAD gas and curtain gas flow 25 psi, ion spray voltage 5500 V, and temperature 500°C. The compound dependent parameters such as the declustering potential (DP), focusing potential (FP), entrance potential (EP), collision energy (CE), cell exit potential (CXP) were optimized during tuning as 35, 25, 10, 20, 12 eV for Alectinib and AlectinibD8, respectively. The collision activated dissociation (CAD) gas was set at 4 psi using nitrogen gas. Quadrupole-1 and quadrupole-3 were both maintained at a unit resolution and dwell time was set at 200 ms for Alectinib and AlectinibD8. The predominant peaks in the primary ESI spectra of AT and ATD8 correspond to the MH^+ ions at m/z 482.6 and 490.6 respectively.

Productions of AT and ATD8 scanned in quadrupole-3 after a collision with nitrogen in quadrupole-2 had a m/z of 396.0 for both respectively. The parent and productions mass spectrums of AT and ATD8 were shown in Figure 2 & 3.

Method validation

Selectivity and Specificity, Limit of Quantification (LOQ)

No significant response was observed at retention times of AT and ATD8 in blank plasma as compared to LLOQ and blank with IS samples. The limit of quantification for this method was proven as the lowest concentration of the calibration curve which was proven as 5.0 ng/ml. Represent chromatograms were shown in Figure 4.

Linearity

Linearity was plotted as a peak area ratio (AT peak area / ATD8 peak area) on the y-axis against AT concentration (pg/ml) on the x-axis. Calibration curves were found to be consistently accurate and precise for AT over a linearity range of 5 to 10000.00 pg/ml. The correlation coefficient was greater than 0.9980 for AT. The %CV was less than 15% and mean %accuracy was ranged between 99.40 - 102.67%. Results were presented in Table 1.

Precision & Accuracy

Intra and inter batch %accuracy for AT was ranged between 94.17-96.00 and 91.66 to 99.34. %CV is 2.36 to 5.10 and 1.64% - 3.24%. Results are presented in Table 2.

Recovery

The mean %recovery for LQC, MQC, HQC samples of AT were 99.85%, 95.30% and 93.54% respectively. The overall mean %recovery and %CV of AT across QC levels is 96.23% and 5.95%. For the ATD8 (internal standard) the mean % recovery and %CV is 91.68% and 7.18%.

Matrix Effect

No significant matrix effect found in different sources of rat plasma tested for AT, ATD8. The %CV was found to be 3.71.

Stability (freeze–thaw, auto sampler, bench top, long term)

Quantification of the AT in plasma subjected to three freeze–thaw cycles (−30°C to room temperature), autosampler (processed), room temperature (Benchtop), long-term stability details were shown in Table 3.

Conclusion

The method described in this manuscript has been developed and validated over the concentration range of 5.0–10000.0 pg/ml in human plasma. The intra and inter-batch precision (%CV) was less than 6.0% and %accuracy ranged from 98.9%–102.4%. The overall %recovery for AT, ATD8 was greater than 90%. The selectivity, sensitivity, precision and accuracy obtained with this method make it suitable for the purpose of the present study. In conclusion, the method used in the present study is easy and fast to perform; it is also characterized with an adequate accuracy, precision, selectivity and stability. The simplicity of the method, and using rapid protein precipitation extraction with less run time of 3.0 min per sample, make it an attractive procedure in high-throughput bioanalysis of Alectinib.

Conflict of interest

Authors declare that, there is no conflict of interest.

REFERENCES

Bennet, R. V., Gamage, C. M. & Fernandez, F. M. 2013. Imaging of biological tissues by desorption electrospray ionization mass spectrometry *Journal of Visualized Experimants* 2013; e50575.

Dobbelstein, M. and Moll, U. 2014. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov ; 13:179–196.

Gode, D. & Volmer, D. A. 2013. Lipid imaging by mass spectrometry - a review. Analyst; 138:1289–1315.

Guidance for industry, March 2003. Bio availability and fed bio equivalence studies for orally administered drug products-general considerations: U.S. Department of Health and Human Services food and drug administration centre for drug evaluation and research (CDER).

Guidance for industry. December 2002. Food-effect bio availability and fed bio equivalence studies: U.S. Department of Health and Human Services food and drug administration centre for drug evaluation and research (CDER).

Guidance for industry. May 2001. Bioanalytical method validation, U.S. Department of Health and Human Services, food and drug administration, center for drug evaluation and research (CDER), Center for biologics evaluation and research (CBER).

Hiroaki Aikawa, Mitsuhiro Hayashi, Shoraku Ryu, Makiko Yamashita, Naoto Ohtsuka, Masanobu Nishidate, Yasuhiro Fujiwara and Akinobu Hamada. 2016. Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. Scientific reports, 6:23749.

Kim, J. H. *et al*. 2008. Label-free calcium imaging in ischemic retinal tissue by TOF-SIMS. Biophys Journal, 94:4095–4102.

Prideaux, B. & Stoeckli, M. 2012. Mass spectrometry imaging for drug distribution studies. Journal of Proteomics; 75:4999–5013.

Seeley, E. H., Schwamborn, K. & Caprioli, R. M. 2011. Imaging of intact tissue sections: moving beyond the microscope. *J Biol Chem.,* 286:25459–25466.

Sugiura, Y. & Setou, M. 2010. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in-situ pharmacometabolomes. *Journal of Neuroimmune Pharmacol* 2010; 5:31–43.

****